InSysBio announces its collaboration with discoveric bio alpha

The project aims at mechanistic modeling of antibodies to predict pharmacokinetics and target occupancy in cerebrospinal fluid

LIMASSOL, Cyprus, March 19, 2025 /PRNewswire/ -- InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with discoveric bio alpha, a biotechnology company taking next generation antibody technologies into Alzheimer's Disease.

Mechanistic modeling will be leveraged to simulate pharmacokinetics (PK) and target occupancy (TO) in cerebrospinal fluid (CSF) of NIDB-3101 being developed by discoveric bio alpha.

Jean-Philippe Courade, CSO of discoveric bio alpha, highlights, "We are excited to implement InSysBio's solutions and wide-ranging modeling experience to enhance the design of preclinical study of NIDB-3101. We hope mechanistic modeling will facilitate accurate dose selection thus accelerating and optimizing further development of our antibody".

Oleg Demin Jr, Scientific Director, InSysBio, comments on the new project, "Our cutting-edge mechanistic modeling approach along with our expertise in modeling of therapeutic antibodies enable us to efficiently develop the PK/TO model based on the published data for other mAbs. We look forward to apply our knowledge and software to support optimization of the experiment design".

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com

About discoveric bio alpha

discoveric bio alpha is a privately owned company part of a group of three separate companies dedicated to the development of novel therapeutics for the treatment of Alzheimer's Disease, Neuroinflammation and Antimicrobial Resistant infections. It is located in Pfäffikon, Switzerland. For more information, visit https://www.discovericbio.com/

Logo - https://mma.prnewswire.com/media/2643083/InSysBio_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/insysbio-announces-its-collaboration-with-discoveric-bio-alpha-302404592.html

SOURCE InSysBio